Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.05
1% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.8M | $4.1M | $5.7M | $8.4M | $10.5M | $11.3M | $10.1M | $12.7M |
| Cost of revenue | $1.6M | $1.3M | $1.7M | $1.6M | $1.7M | $25.0M | $1.3M | $1.7M |
| Gross profit | $3.2M | $2.8M | $4.0M | $6.8M | $8.8M | −$13.7M | $8.7M | $11.0M |
| Gross margin | 66.7% | 69.4% | 70.5% | 80.8% | 83.7% | -120.4% | 86.9% | 86.3% |
| R&D | $3.0M | $3.0M | $3.3M | $1.5M | $683.0K | $598.0K | $221.0K | $98.6K |
| Operating income | −$30.6M | −$27.0M | −$25.6M | −$23.1M | −$21.5M | −$22.8M | −$24.3M | −$24.2M |
| EBITDA | −$30.2M | −$26.3M | −$24.1M | −$21.4M | −$18.8M | −$20.5M | −$22.1M | −$17.6M |
| Net income | −$27.2M | −$24.1M | −$21.4M | −$20.7M | −$19.9M | −$20.5M | −$19.8M | −$23.2M |
| Net margin | -566.5% | -588.7% | -375.4% | -247.9% | -189.4% | -180.9% | -196.9% | -182.6% |
| EPS (diluted) | -0.07 | -0.06 | -0.04 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $11M | $-0.00 | $-0.01–$-0.00 | 1 |
| 2027 | $15M | $-0.00 | $-0.00–$-0.00 | 1 |
| 2028 | $21M | $-0.00 | $-0.00–$-0.00 | 1 |
Forward consensus · source: Financial Modeling Prep
IMPEDIMED LTD ORD
No one on the platform currently holds IPDQF.
No tracked institution reports a position in IPDQF as of their last filing.
No one on the platform has traded IPDQF yet.
| $10M |
| — |
| ELXMFNova Eye Medical Limited | $0.01 | +0.00% | $4M | — |
| FNCHFinch Therapeutics Group, Inc. | $8.70 | +16.00% | $14M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.4× sales vs its 12.2× historical median P/S.
Fair value ≈ $0.15 · price $0.00 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.